| abstract |
Use of a therapeutic LPL S447X for the preparation of a pharmaceutical composition for the treatment of a condition sensitive to LPL in a subject, where the therapeutic LPL S447X is selected from the group consisting of: a) a LPL S447X protein comprising a sequence of amino acids that have at least 90% sequence identity with SEQ ID NO: 3 when optimally aligned, and where the LPL S447X protein lacks amino acids corresponding to amino acids 447 and 448 of SEQ ID NO: 3 when optimally aligned ; b) an isolated nucleic acid molecule comprising a nucleotide sequence encoding the LPL S447X protein as defined in a); and, c) an LPL S447X nucleic acid encoding the LPL S447X protein as defined in a); and, where the LPL-sensitive condition is selected from the group consisting of: complete LPL deficiency, chylomicronemia, hyperlipidemia, partial LPL deficiency, pancreatitis, hypertriglyceridemia, hypoalphalipoproteinemia (low HDL cholesterol), cardiovascular disease, coronary heart disease, coronary artery disease, atherosclerosis, angina pectoris, hypertension, cerebrovascular disease, coronary restenosis, peripheral vascular disease, diabetes, cachexia and obesity. |